Publication Online – TBD Print – TBD
This guideline is currently in development and will cover eight key questions. It will discuss how moderately hypofractionated and ultrahypofractionated schedules compare to conventional regimens in terms of
prostate cancer control, toxicity and quality and the effect of patient and tumor factors on the appropriateness of hypofractionated radiation therapy. It will also make recommendations regarding appropriate dose-fractionation for both moderate and ultrahypofractionation. Next, the guideline will look at normal tissue constraints and treatment volumes for hypofractionation and the role of image-guided and intensity-modulated radiation therapy in using these regimens.
ResourcesImplementation of Hypofractionated Prostate RT in the US: A NCDB AnalysisLong-term patient reported outcomes from a phase III randomized prospective trial of conventional vs. hypofractionated RT for localized prostate cancerClinical Controversies
Author SocietyAmerican Society for Radiation OncologyAmerican Urologic Association
ASTRO guidelines present scientific, health, and safety information and may reflect scientific or medical opinion. They are available to ASTRO members and the public for educational and informational purposes only. Commercial use of any content in this guideline without the prior written consent of ASTRO is strictly prohibited.